Generated by All in One SEO v4.9.6.2, this is an llms.txt file, used by LLMs to index the site. # Neurvati Rewiring the neuroscience ecosystem. ## Sitemaps - [XML Sitemap](https://neurvati.com/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [GRIN Therapeutics’ Pivotal Phase 3 Beeline Study Initiated in Europe](https://neurvati.com/wp-content/uploads/Neurvati_2026_PR_EUAprilRelease_FINAL.pdf#new_tab) - [GRIN Therapeutics Announces First Patient Dosed in Global Phase 3 Beeline Trial of Investigational Radiprodil for GRIN-Related Neurodevelopmental Disorder](https://neurvati.com/wp-content/uploads/Neurvati_2026_PR_FPI_Release_FINAL-1.pdf#new_tab) - [GRIN Therapeutics to Present on Global Phase 3 Beeline Clinical Trial of Radiprodil at American Epilepsy Society Annual Meeting](https://neurvati.com/wp-content/uploads/AES-2025-Curtain-Raiser-DRAFT_FINAL-12.2.pdf#new_tab) - [Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer](https://neurvati.com/wp-content/uploads/Neurvati_2025_PR_Release_Carlos_Final-11-12.pdf#new_tab) - [GRIN Therapeutics Presents Multiple Clinical Development Updates for Radiprodil at 2025 ILAE International Epilepsy Congress](http://neurvati.com/wp-content/uploads/Neurvati_ILAE_PressReleaseDraft-FINAL.pdf#new_tab) - [Neurvati Neurosciences and GRIN Therapeutics Announce Appointment of Gail Farfel, PhD to Their Boards of Directors](http://neurvati.com/wp-content/uploads/Dr.-Farfel-BOD-Press-Release.pdf#new_tab) - [GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America](http://neurvati.com/wp-content/uploads/GRINTx_AP_PR_21.5.25.pdf#new_tab) - [GRIN Therapeutics Receives Priority Medicines (PRIME) Designation from EMA for Radiprodil in the Treatment of GRIN-Related Neurodevelopmental Disorder](https://neurvati.com/wp-content/uploads/PRIME-EMA-Designation-Press-Release-Final.pdf#new_tab) - [GRIN Therapeutics Receives Positive Opinion for EU Orphan Designation for Radiprodil for Treatment of GRIN-Related Neurodevelopmental Disorder](http://neurvati.com/wp-content/uploads/EU-OD-Press-Release_5.1.pdf#new_tab) - [GRIN Therapeutics Receives FDA Orphan Drug Designation for Radiprodil for the Treatment of GRIN-Related Neurodevelopmental Disorder](http://neurvati.com/wp-content/uploads/Radiprodil-Orphan-Drug-Announcement-Release-FINAL.pdf#new_tab) - [GRIN Therapeutics Receives FDA Breakthrough Therapy Designation for Radiprodil](http://neurvati.com/wp-content/uploads/Radiprodil-Breakthrough-Therapy-Designation-Final.pdf#new_tab) - [GRIN Therapeutics Presents Data from Honeycomb Trial of Radiprodil at the American Epilepsy Society Annual Meeting](http://neurvati.com/wp-content/uploads/AES-2024-Press-Release-Final-PDF.pdf#new_tab) - [GRIN Therapeutics to Present Data from Honeycomb Trial of Investigational Radiprodil in GRIN-Related Neurodevelopmental Disorder](https://neurvati.com/wp-content/uploads/AES-2024-Curtain-Raiser.pdf#new_tab) - [GRIN Therapeutics Announces Initiation of Astroscape Clinical Trial of Radiprodil for Treatment of Tuberous Sclerosis Complex and Focal Cortical Dysplasia Type II](https://neurvati.com/wp-content/uploads/GRIN-Therapeutics-Astroscape-Clinical-Trial-PR.pdf#new_tab) - [Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors](https://neurvati.com/wp-content/uploads/Neurvati-Dunsire-BOD-Appointment-PR.pdf#new_tab) - [GRIN Therapeutics Announces Positive Topline Data from Honeycomb Trial of Radiprodil in GRIN-Related Neurodevelopmental Disorder](http://neurvati.com/wp-content/uploads/Honeycomb-Topline-Data-Press-Release.pdf#new_tab) - [GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders](https://www.businesswire.com/news/home/20230323005287/en/GRIN-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1B-Clinical-Trial-with-Radiprodil-for-Treatment-of-GRIN-related-Disorders#new_tab) ## Pages - [Homepage](https://neurvati.com/) - At Neurvati, we’re taking a different approach to advancing neuroscience product development with the goal of accelerating treatment options and access for patients in need, globally. - [Privacy Policy](https://neurvati.com/privacy/) - At Neurvati, we’re taking a different approach to advancing neuroscience product development with the goal of accelerating treatment options and access for patients in need, globally. - [Cookie Policy](https://neurvati.com/cookie-policy/) ## Portfolio Items - [Anne-Marie Li-Kwai-Cheung](https://neurvati.com/leadership/jason-lettiere-2/) - [Pierre Jacquet, MD, PhD](https://neurvati.com/leadership/pierre-jacquet-md-phd/) - [Jonathan Freeman, PhD](https://neurvati.com/leadership/jonathan-freeman/) - [Kiran Reddy, MD](https://neurvati.com/leadership/kiran-reddy/) - [Gail Farfel, PhD](https://neurvati.com/leadership/gail-farfel-phd/) - [Nicholas Galakatos, PhD](https://neurvati.com/leadership/nicholas-galakatos-2/) - [Elliott Ruiz, MBA](https://neurvati.com/leadership/elliott-ruiz/) - [Carlos Martin](https://neurvati.com/leadership/carlos-martiin/) - [Abena Roberts](https://neurvati.com/leadership/abena-roberts/) - [Nicole Tantillo](https://neurvati.com/leadership/nicole-tantillo/) - [Aneeta Saxena](https://neurvati.com/leadership/aneeta-saxena/) - [Dayong Li](https://neurvati.com/leadership/dayong-li/) - [Emily Miller](https://neurvati.com/leadership/emily-miller/) - [Marjory Levey](https://neurvati.com/leadership/marjory-levey/) - [Martha Rutkowski](https://neurvati.com/leadership/martha-rutkowski/) - [Meghan Macaraeg](https://neurvati.com/leadership/meghan-macaraeg/) - [Bruce Leuchter, MD](https://neurvati.com/leadership/bruce-leuchter/) - [Jason Lettiere](https://neurvati.com/leadership/jason-lettiere/) - [Dana Williams](https://neurvati.com/leadership/dana-williams/) - [Hillary Savoie, PhD](https://neurvati.com/leadership/hillary-savoie-phd/) - [Vijay Rai](https://neurvati.com/leadership/vijay-rai-2/) - [Jennifer Pinheiro](https://neurvati.com/leadership/jennifer-pinheiro-2/) - [Jemima Monchery](https://neurvati.com/leadership/jemima-monchery-2/) - [Benjamin Millen](https://neurvati.com/leadership/benjamin-millen-2/) - [Bob Macnair](https://neurvati.com/leadership/bob-macnair/) - [Walter Lunsmann, MS, MBA](https://neurvati.com/leadership/walter-lunsmann-ms-mba/) - [Alex Lubat](https://neurvati.com/leadership/alex-lubat/) - [Ashley Horn](https://neurvati.com/leadership/ashley-horn-2/) - [Kenneth Hess, PhD, MBA](https://neurvati.com/leadership/kenneth-hess-2/) - [Russell Chin, MD](https://neurvati.com/leadership/russell-chin-2/) - [Deborah Dunsire, MD](https://neurvati.com/leadership/deborah-dunsire/) ## Categories - [Press Release](https://neurvati.com/category/press-release/) ## Portfolio Categories - [Leadership](https://neurvati.com/leadership/leadership/) - [Board of Directors](https://neurvati.com/leadership/board-of-directors/) - [Management](https://neurvati.com/leadership/management/)